Kyntra Bio, Inc. (KYNB) vs Rein Therapeutics Inc. (RNTX)
A side-by-side comparison of Kyntra Bio, Inc. and Rein Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KYNB
Kyntra Bio, Inc.
$5.96HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RNTX
Rein Therapeutics Inc.
$0.83HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — KYNB vs RNTX
growth of $100 · dividends reinvested · last 2yKYNB -28.8% (-15.6%/yr)RNTX -61.1% (-37.6%/yr)KYNB compounded faster over this window
KYNB RNTX
KYNB vs RNTX: by the numbers
- •KYNB is the larger company ($24M vs $23M market cap).
- •KYNB is profitable (3967.77% net margin) while RNTX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | KYNB | RNTX |
|---|---|---|
| P/S ratio | 5.23 | N/A |
| P/B ratio | N/A | 2.26 |
Profitability
| Metric | KYNB | RNTX |
|---|---|---|
| Gross margin | 91.37% | 0.00% |
| Operating margin | -712.66% | 0.00% |
| Net margin | 3967.77% | 0.00% |
| ROE | N/A | -487.90% |
| ROIC | -78.16% | -36.89% |
Growth (annualized)
| Metric | KYNB | RNTX |
|---|---|---|
| Revenue CAGR (5Y) | -51.49% | N/A |
| Total return CAGR (5Y) | -52.67% | N/A |
Frequently asked
- Is KYNB or RNTX more profitable?
- KYNB runs the higher net margin — KYNB at 3967.77% versus RNTX at 0.00%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.